M Pharmaceutical, a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological disorders, announced that it has entered into a manufacturing supply agreement with Rishena of Changzhou, China, to manufacture the Company's Trimtec gastric functional neurostimulation device.
Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets.
The devices will be fully programmable and rechargeable through an abdominal belt. Rishena commits, at its expense, to obtain ISO 13485 certification1 for Trimtec manufacturing prior to the Company’s commercial launch of Trimtec.
"Our agreement with Rishena is an important step forward in the development of Trimtec for the North and South American markets," said Dr. Martin Mintchev, the President and CEO of M Pharma.
"We are delighted to collaborate with an experienced and respected medical device manufacturer such as Rishena and look forward to successful collaboration with them."